Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Uzbekistan launches €9.46 billion green energy push, covering nation’s power needs - 2Bondi Beach survivor criticizes police for inaction during terror attack
- 3Last supermoon of the year, the cold moon, seen across the U.S.: See the photos
- 4Step by step instructions to Choose the Right Auto Crash Legal counselor for Your Case
- 5All that You Really want to Be familiar with Dental Inserts Facilities
- Why the chemtrail conspiracy theory lingers and grows – and why Tucker Carlson is talking about it
- Here's how 'Bridgerton' fans can watch the first episode of Season 4 before its Netflix release later this month
- Gartex Texprocess India to showcase innovations across textile ecosystem
- Whale stranded off Germany for days free again
- Key Caper d: A Survey of \Procedure and Tomfoolery Released\ Tabletop game
- The Most Enrapturing Authentic Milestones to Visit
- Interstellar comet 3I/ATLAS will fly by Earth Friday. Here are the latest images
- Dramatic Dominance d: A Survey of \Feelings in front of an audience\ Theater Play
- Sun storms are powered by a magnetic engine 16 Earths deep, study finds
